Chinese herbal medicine has been commonly used in the treatment of postinfectious cough. The aim of this review is to systematically evaluate the efficacy and safety of Chinese herbal medicine for postinfectious cough. An extensive search for RCTs was performed using multiple electronic databases, supplemented with a manual search. All studies included were confirmed with specific inclusion criteria. Methodological quality of each study was examined according to the Cochrane risk of bias assessment. Quality of evidence was evaluated using rating approach developed by GRADE working group. The literature search yielded 352 results, of which 12 RCTs satisfied the inclusion criteria, offering moderate-to-high levels of evidence. Methodological quality was considered high in three trials, while in the other nine studies the unclear risk of bias was in the majority. Findings suggested that, compared with western conventional medicine or placebo, Chinese herbal medicine could effectively improve core symptoms of postinfectious cough, act better and have earlier antitussive effect, and enhance patients’ quality of life. No serious adverse event was reported.

1. Introduction

Patients who complain of a persistent cough lasting >3 weeks but not >8 weeks after experiencing the acute symptoms of an upper respiratory tract infection are considered to have a postinfectious cough (PIC) [1]. PIC is supposed to be the most common cause of subacute cough [2], which is distinguished from the chronic cough by the duration of coughing [3]. For adults, retrospective studies of unselected patients with a history of upper respiratory tract infection showed that the frequency of PIC ranged from 11 to 25% [4], which increased to the range from 25 to 50% during outbreaks of atypical pathogens infections [5, 6]. Respiratory viruses, *M. pneumoniae*, *Chlamydia pneumonia*, and some specific bacteria have been implicated in the cause of PIC [7, 8]. The pathogenesis of the PIC has not been clearly recognized. It was frequently thought to be relevant to multiple factors involving disruption of epithelial integrity, widespread airway inflammation, and bronchial hyperresponsiveness [9–12].

Although PIC is self-limited and will usually resolve on its own in time, persistent cough always incurs much health troubles and economic miseries for patients and their surroundings. Thus, medication therapy is imperative sometimes. Up to now, optimal treatment of western conventional medication (WCM) for patients with PIC is not known [1]. Symptomatic therapeutic medications including antihistamine, decongestant, and ipratropium bromide are being commonly used. Besides, brief course of inhaled or oral corticosteroids [13] has sometimes been administered in view of airway inflammations. But corticosteroids were generally used just in patients with severe paroxysms of PIC for their remarkable side effects [1]. Central acting antitussive agent such as codeine or dextromethorphan would be considered, as a last resort, in those patients who are resistant to other treatment approaches; however, there have been no clinical trials conducted to support its effect [1]. In addition, antibiotics are usually abused in treatment of PIC. Therefore, research for optimal treatment of PIC is particularly needed [14, 15].

TCM has unique understanding of PIC and has established its own diagnosis and treatment approach. In TCM theory system, PIC, equivalent to the category of exogenous
cough, is caused by invasion of external evil factors (wind-evil, cold-evil, summer-damp-evil, wet-evil, dryness-evil, and fire-evil). These factors disturb or suppress Qi activity in the lung, leading to acute cough. If things continue this way, the lung-Qi would be damaged and unable to drive evils out, leaving external evils lingering in the lung for a long time. In this case, patients would suffer a fairly long duration of cough. With thousands of years of experience, TCM clinicians summarized the most common pathomechanism of PIC as “disorder Qi activity in the lung” due to “wind-evil invading the lung.” The corresponding therapeutic method is “dispelling wind and dispersing the lung-Qi.” PIC is a disease with complex pathogenic conditions including phlegm turbidity and deficiency of the lung-Yin. So flexible treatment based on syndrome differentiation is important.

An increasing number of clinical trials on CHM for PIC have been performed. This current systematic review aims to collect the evidence from RCTs to evaluate the therapeutic effect and safety of CHM in the management of PIC.

2. Methods

2.1. Research Protocol. All methods were performed according to a predefined, unpublished protocol, which consisted of the search databases, detailed research question, search strategies, and eligibility criteria. The detailed research question included study design, patient characteristics, interventions, and outcomes.

2.2. Database and Search Strategies. Literature searches were conducted to identify reports of randomized controlled trials involving CHM for PIC in the following preliminary determined electronic databases: Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, EMBASE, MEDLINE (PubMed), Cqvip Database, Google Scholar, Scholarly and Academic Information Navigator (CiNii), and Cochrane Library from inception to July 2013. Ongoing registered clinical trials were searched on the website of Chinese clinical trial registry (ChiCTR) (http://www.chictr.org/). Searches for relevant conference proceedings, unpublished literature, and studies (Table 1) included in previous relevant systematic reviews were performed. Moreover, manual searches for bibliographies of all retrieved literature sources were conducted for additional references. No language restriction was applied.

The following phrases and their derivatives or relevant terms were utilized singly or in combination: “post-infectious cough,” “subacute cough,” “cough post influenza,” “postviral cough,” “post-cold cough,” “whooping cough,” “Chinese herbal medicine,” “traditional Chinese medicine,” and “randomized controlled trial.” The search terms were modified to adapt to different databases with a highly sensitive search strategy developed by the Cochrane Collaboration [16]. We contacted authors for further information or clarification. Searching work was done by two reviewers (Wei Liu and Hong-Li Jiang) independently. Searching results were cross-checked for accuracy.

2.3. Inclusion Criteria

2.3.1. Types of Studies. All relevant randomized controlled trials or quasirandomized controlled trials that were published before July 20, 2013 were considered, regardless of blinding.

2.3.2. Types of Participants. Any patients with diagnosed and existing PIC, of either gender, any profession or ethnicity, and any ages ≥12, were included. Those without description of diagnostic criteria but stated patients with definite PIC were also considered.

2.3.3. Types of Interventions. Studies involving a comparison between CHM alone or in combination with WCM and the same WCM or placebo as controls were included. CHM included herbal extracted product, Chinese patent medicine (CPM), and self-modified herbal formula. CHM could be of any dose, duration, dosage form, and route of administration. Studies involving cointerventions of traditional extrapulmonary therapies such as acupuncture, cupping, or point application were excluded.

2.3.4. Outcomes. Primary outcomes measures were as follows: (1) cough symptom score, which consists of the daytime-score and the nighttime-score, ranging from 0 to 6 [17]; (2) cough relief time, defined as both the daytime-score and the nighttime-score ≤1, which lasted for 48 hours; (3) cough disappearance time, defined as both of the daytime-score and the nighttime-score = 0, which lasted for 48 hours. Secondary outcome measures were as follows: (1) Obvious effective rate, defined as reduced rate of symptoms score ≥70% according to the Guiding Principle of Clinical Research on New Drugs of TCM [18, 19]; (2) quality-of-life (QoL) score, evaluated using Cough-Specific Quality-of-Life Questionnaire (CQLQ) [20] or Leicester Cough Questionnaire (LCQ) [21]; (3) adverse events.

2.4. Studies Selection and Data Extraction. Two reviewers (Wei Liu and Hong-Li Jiang) independently screened the titles and abstracts of searching results against prespecified inclusion criteria to identify potential relevance that required full texts for further identification. Disagreements were resolved by consensus. All articles included were judged by the third reviewer (Bing Mao).

Two reviewers (Wei Liu and Hong-Li Jiang) systematically extracted data regarding study design, demographic characteristics, interventions, and outcome measures independently. Discrepancies were resolved by discussion between the two reviewers or by consultation with the third arbitration (Bing Mao).

2.5. Qualities Assessment. We used risk of bias assessment tool recommended by the Cochrane Collaboration to address the following six domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and “other bias” [22]. The risk of bias for each item was summarized as three levels: low,
| Study ID               | T/C  | M/F  | Age (mean ± SD or range, Y) | Study design | Interventions                                                                 | Treating duration (D) | Outcomes                          | Dropout (T/C) | Adverse events (T/C) |
|-----------------------|------|------|----------------------------|--------------|-------------------------------------------------------------------------------|----------------------|------------------------------------|---------------|----------------------|
| Fujimori et al., 2001, Japan [26] | 13/12 | 2/33 | T: 31–81 C: 23–67          | RCT          | T: bakumondo-to extract granules; C: dextromethorphan                        | Seven                | Cough symptom score               | 1 patient in the control group dropped out because of failure to bring a cough diary | No           |
| Iriyune et al., 2011, Japan [27] | 9/11  | 8/12 | T: 60.7 ± 12.7 C: 48.5 ± 19.8 | Multicentre; RCT; open-label | T: procaterol hydrochloride (Meptin tablets) plus bakumondo-to extract granules (TJ-29); C: procaterol hydrochloride (Meptin tablets) | Fourteen             | Cough symptom score               | 1 patient in the control group was excluded due to allocation error | No Palpitation and hands tremor considered to be attributed to Meptin tablets were observed in 6 patients (4/2) Rash considered to be attributed to TJ-29 treatment was observed in 1 patient in the trial group |
| Qin, 2011, China [28]    | 30/30 | 31/29| T: 40.07 ± 14.14 C: 41.87 ± 13.57 | RCT          | T: Er-li decoction plus compound methoxyphenamine capsules; C: compound methoxyphenamine capsules T: Xuan-fei Zhi-sou decoction; C: pseudoephedrine hydrochloride, chlorpheniramine maleate, and dextromethorphan hydrobromide solution | Ten                  | Obvious effective rate            | No            | NS                  |
| Wang, 2011, China [29]    | 30/30 | 33/27| T: 37.03 ± 9.946 C: 33.50 ± 9.662 | RCT; open-label | T: Qing-fei Zhi-ke decoction; C: jizhi syrup (CPM)                             | Seven                | Obvious effective rate; cough relief time | NS            | No                  |
| Song, 2012, China [30]    | 30/30 | 19/41| T: 45.23 ± 11.25 C: 45.45 ± 10.52 | RCT          | T: Qing-fei Zhi-ke decoction; C: jizhi syrup (CPM)                             | Fourteen             | Cough symptom score; obvious effective rate; LCQ score; cough relief time | 6 patients dropped out without explanations provided | No            |
| Study ID                  | N* T/C | Number M/F | Age (mean ± SD or range, Y) | Study design | Interventions                                                                 | Treating duration (D) | Outcomes                                                                 | Dropout (T/C) | Adverse events (T/C)                                                                 |
|--------------------------|--------|------------|-----------------------------|--------------|-------------------------------------------------------------------------------|-----------------------|---------------------------------------------------------------------------|---------------|-----------------------------------------------------------------------------------|
| Wu et al., 2011, China [31] | 50/50  | 49/51      |                             | RCT          | T: Shu-feng Xuan-fei decoction; C: chlorpheniramine maleate tablets plus pentoxyverine citrate tablets | Five                 | Cough symptom score                                                       | 9 patients dropped out because of being lost to follow-up, poor compliance, and concomitantly taking other antitussive drugs (4/5) |
| Zhang et al., 2008, China [32] | 208/69 | 114/163    |                             | Multicentre; RCT; DB; parallel-group | T: Su-huang Zhi-ke capsule (CPM); C: Zhi-ke Ning-sou capsule (CPM) | Seven                 | Obvious effective rate; cough relief time; cough disappearance time      | 6 patients dropped out without explanations provided (4/2)                                                             |
| Wu, 2011, China [33]     | 143/134| 122/155    |                             | RCT; DB; placebo-controlled; parallel-group | T: extract granules of Feng-han decoction or Feng-re decoction; C: placebo | Ten                   | Obvious effective rate; cough relief time                                  | 23 patients dropped out. Of which, 10 patients were lost to follow-up (6/4), 12 patients were required to withdraw (9/3), and 1 patient in the control group refused to take drug because of inefficacy |
| An, 2002, China [34]     | 30/30  | 26/34      |                             | RCT; open-label | T: Zhi-ke Gu-biao decoction; C: pentoxyverine citrate tablets                   | Fourteen              | Obvious effective rate; cough relief time                                  | NS            | Adverse events without further specifications were observed in 37 patients (17/20) |
| Jiang, 2013, China [35]  | 57/57/59 (H/L/C) | 72/101 |                             | Multicentre; RCT; DB; placebo-controlled; parallel-group | H: Qing-feng Gan-ke granules (CPM); L: Qing-feng Gan-ke granules; C: placebo | Fourteen              | Cough symptom score; CQLQ score; Cough symptoms score | 3 patients were excluded due to violating protocol (H: 1/C:2); 5 patients dropped out due to being lost to follow-up (H:3/L:2); 4 patients dropped out due to other reasons (H: 1/L:2/C:1) | Dizziness, arm itching, urinary tract infection, leukocytosis, abnormal liver function, and rough tongue were observed in 9 patients (H: 4/L:4/C:1) |
Table 1: Continued.

| Study ID       | N* T/C | Number M/F | Age (mean ± SD or range, Y) | Study design | Interventions                                                                 | Treating duration (D) | Outcomes                             | Dropout (T/C) | Adverse events (T/C) |
|----------------|--------|------------|-----------------------------|--------------|--------------------------------------------------------------------------------|-----------------------|--------------------------------------|---------------|----------------------|
| Min, 2011, China [36] | 75/74/73 (T/I/C) | 108/114 | T: 29.21 ± 7.37 I: 28.21 ± 7.37 C: 30.12 ± 6.01 | RCT          | T: Bu-tu Xuan-fei decoction; I: Bu-tu Xuan-fei decoction plus compound methoxyphenamine capsules; C: compound methoxyphenamine capsules | Seven                 | Obvious effective rate; NS       | NS            | Stomach bloating was observed in 4 patients in the trial group; dizziness, drowsiness, and fatigue were observed in 12 patients (I:5/C:7) |
| Huang, 2009, China [37] | 30/30 | 31/29 | T: 32.63 ± 9.44 C: 35.20 ± 11.00 | RCT; SB     | T: Ke-ping decoction; C: loratadine tablets plus dextromethorphan                | Seven                 | Obvious effective rate; cough relief time | No            | Drowsiness was observed in 1 patient in the control group |

N*: number; T: trial group; C: control group; H: high dosage group; L: low dosage group; I: integrated group; NS: not specified; D: day; DB: double-blind; SB: single-blind.
high, and unclear. The risk of bias graph was made using RevMan 5.2 software.

We also used GRADE approach to assess the quality of the evidence for each individual outcome. Besides within-study limitations of design and execution (methodological quality), the GRADE approach incorporates comprehensive considerations of the following four factors: directness of evidence, inconsistency of results, imprecision, and publication bias [23, 24]. Accordingly, we graded the quality of evidence as very low, low, moderate, or high.

The first reviewer (Wei Liu) performed the quality assessments with supervision from the other two reviewers (Hong-Li Jiang and Bing Mao).

2.6. Data Analysis. In this review, a formal meta-analysis would not be conducted for the predicted large heterogeneity across trials [25]. Therefore, a narrative synthesis approach was applied.

3. Results

3.1. Description of Included Studies. The search strategies came up with 352 potentially relevant citations. Twelve trials involving 1289 subjects satisfied all the inclusion criteria (Figure 1). One unpublished study [35] searched on the website of ChiCTR was included (registration number ChiCTR-TRC-12002297). Patients included in all studies were explicitly diagnosed as having PIC according to the nationwide unified western medicine diagnostic criteria [17] or ACCP Evidence-Based Clinical Practice Guidelines. TCM syndrome differentiation was identified based on the recognized guiding principles [18, 38]. TCM syndrome of each patient was specified in ten studies and it was defined as “syndrome of wind evil invading the lung” in seven studies. As to the interventions, two studies compared CHM with placebo [33, 35], five studies compared CHM with WCM [26, 29, 31, 34, 37], and two studies compared CHM adjuvantly used with WCM to the same WCM alone [27, 28], two studies compared two CPMs [30, 32]. Three trials reported a follow-up period to evaluate the sustained or subsequent effect of interventions [31, 33, 35]. CHMs used in the studies included were totally different. But nine of them [28–33, 35–37] were prescribed based on the same TCM therapeutic principle of “dispelling wind and dispersing the lung-Qi” (Table 2).

3.2. Quality Assessment of Included Studies. In general, the unclear risk of bias is in the majority. Very limited information was available in many studies to permit a judgment of whether the risk of bias existed (Table 3).

Appropriate random component in the sequence generation process was described in six trials [30–33, 35, 36]. One study [37] implemented a quasi random method by allocating patients according to sequence number of visiting. In this situation, patients’ assignments could possibly be foreseen, which would introduce high selection bias.

Allocation concealment was presented in three trials [32, 33, 35]. One study [27] only pointed “envelopes” but did not specify whether they were sequentially numbered, properly opaque, or sealed. Other studies failed to show any information of allocation concealment. Thus, whether the randomization was effectively conducted was doubtful, leading to an unclear risk of selection bias.

Blinding was not addressed in most studies. Only three studies [32, 33, 35] claimed to be double-blind and elaborated the blinding method that was unlikely to be broken, contributing to a sufficient protection against bias. One study [37] stated single blind just in broad terms, so the performance risk of bias was classified as “unclear.” Three studies [27, 29, 34] were open-label trials, and the patients’ knowledge of interventions they received was likely to result in a high risk of detection bias.

3.3. Quality of Evidence of Included Studies. The “GRADE profiler” of the Cochrane Collaboration Network was used to assess the individual outcome. The quality of evidence was labeled as moderate to high (Table 4).

3.4. Outcome Measures of Included Studies. Forest plots were used to show the statistical results of some outcome measures. Two studies [35, 36] divided patients into three groups, so each of them was regarded as two RCTs in the final analysis.

3.4.1. Cough Symptom Score. Cough symptom score was reported in five studies. Two studies [26, 27] showed no significant difference between bakumondo-to group and WCM group at the last visit of view, but both of them found that bakumondo-to group had a more quick antitussive effect. Three studies [30, 31, 35] concluded significant difference between the trial group and the control group (Figure 2).

3.4.2. Cough Relief Time. Seven trials selected cough relief time as an outcome measure. For this indicator, six studies demonstrated statistically significant difference between the trial group and the control group [29, 30, 33–35, 37], indicating a more rapid cough relief effect of CHM, of which two studies [33, 35] estimated cough relief time for each group using Kaplan-Meier method (median cough relief time: T = 6 d, C = 7 d; log-rank test P = 0.026 [33]; median cough relief time: H = 4 d, L = 4 d, C = 6 d; log-rank test P < 0.001 [35]). In the other study [32], significant difference between two CPMs (Su-huang Zhi-ke capsule and Zhi-ke Ning-sou capsule) was not observed in statistical analysis (Figure 3).

3.4.3. Cough Disappearance Time. Cough disappearance time was investigated in two researches. One study [35] showed better effect favoring CHM groups and detected statistical significance on difference across three groups (median cough disappearance time: H = 8 d, L ≥ 10 d, C ≥ 10 d; log-rank test P < 0.001). The other study [32] demonstrated the same effect of two CPMs (Su-huang Zhi-ke capsule and Zhi-ke Ning-sou capsule) (MD = −0.11, 95% [0.83, 0.61]).

3.4.4. Obvious Effective Rate. Nine trials selected “effective rate” (ER) as an outcome measurement. In these studies, “rate ratio” (RR) was calculated as the ratio between the proportion...
| Study ID       | CHM intervention                                      | TCM principle of CHM                                                                 | TCM syndrome of patients                                                                 |
|---------------|-------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Fujimori et al., 2001 [26] | Extract granules of bakumondo-to (Mai-men-dong decoction in Chinese Pinyin) | Nourishing Yin; descending the upgoing lung-Qi; harmonizing the stomach and lung      | Syndrome of lung and stomach Yin deficiency and disharmony between the lung and the stomach |
| Irifune et al., 2011 [27] | Extract granules of bakumondo-to (Mai-men-dong decoction in Chinese Pinyin) | Nourishing Yin; descending the upgoing lung-Qi; harmonizing the stomach and lung      | Syndrome of lung and stomach Yin deficiency and disharmony between the lung and the stomach |
| Qin, 2011 [28] | Er-li decoction                                       | Dispelling wind and dispersing the lung-Qi, resolving phlegm and nourishing the lung-Yin | Syndrome of wind-sputum evil invading the lung                                           |
| Wang, 2011 [29] | Xuan-fei Zhi-sou decoction                           | Dispelling wind and dispersing the lung-Qi, resolving phlegm and calming down cough   | Syndrome of wind evil invading the lung                                                 |
| Song, 2012 [30] | Qing-fei Zhi-ke decoction                            | Dispelling wind and dispersing the lung-Qi, eliminating heat and calming down cough   | Syndrome of wind-heat evil attacking the lung                                          |
| Wu et al., 2011 [31] | Shu-feng Xuan-fei decoction                          | Dispelling wind and dispersing the lung-Qi, relieving airway spasm and calming down cough | Syndrome of wind-evil invading the lung                                               |
| Zhang et al., 2008 [32] | Su-huang Zhi-ke capsule                              | Dispelling wind and dispersing the lung-Qi, expelling cold and relieving exterior; dispelling wind and dispersing the lung-Qi, eliminating heat and relieving exterior | Syndrome of wind-cold evil fettering the lung; syndrome of wind-heat evil attacking the lung |
| Wu, 2011 [33] | Feng-re decoction; Feng-han decoction                | Regulating activity of the lung-Qi and resolving phlegm, tonifying the protective Qi and strengthening exterior | Syndrome of wind evil invading the lung                                                |
| An, 2002 [34] | Zhi-ke Gu-biao decoction                             | Dispelling wind and dispersing the lung-Qi, expelling cold and relieving exterior; dispelling wind and dispersing the lung-Qi, eliminating heat and relieving exterior | Syndrome of wind evil invading the lung                                                |
| Jiang, 2013 [35] | Qing-feng Gan-ke granules                            | Dispelling wind and dispersing the lung-Qi, expelling cold and relieving exterior; dispelling wind and dispersing the lung-Qi, eliminating heat and relieving exterior | Syndrome of wind evil invading the lung                                                |
| Min, 2011 [36] | Bu-tu Xuan-fei decoction                             | Dispelling wind and dispersing the lung-Qi, tonifying the spleen and nourishing the lung-Yin | Syndrome of wind evil invading the lung                                                |
| Huang, 2009 [37] | Ke-ping decoction                                    | Dispelling wind and dispersing the lung-Qi, relieving sore throat and nourishing the lung-Yin | Syndrome of wind evil invading the lung and Heat evil injuring the lung-Yin            |
of responders in the trial group and the proportion of responders in the control group. Responders were defined as those patients with an improvement rate of symptoms score ≥ 70%. For this indicator, eight studies were statistically significant, showing that CHM can improve clinical core symptoms of PIC [28, 30, 32–37]. The same effect of CHM and WCM was reported in one study [29] (Figure 4).

3.4.5. Quality-of-Life Score. Quality-of-life (QoL) evaluation was conducted in two studies. Both of them showed that CHM possessed a better effect in improving patients’ quality of life. One study [35] calculated CQLQ total score and demonstrated significant difference across groups ($P < 0.00001$, MD = −8.34, 95% [−11.63, −5.05]). The other study [30] recorded physical, psychological, and social domains
of LCQ and difference of post treatment score for the three domains of a self-modified decoction (Qing-fei Zhi-ke decoction) and a CPM (Jizhi syrup) was statistically significant (MD and 95% for physical, psychological, and social domains, respectively: MD = −0.90, 95%[−1.01,−0.80]; MD = −3.00, 95%[−3.08,−2.92]; MD = −0.72, 95%[−0.87,−0.56]).

3.5. Adverse Events. In general, CHM was claimed to have fewer side effects compared with WCM. Adverse events were mentioned in eleven studies. Four studies [25, 28, 29, 33] reported that no adverse events were observed at the end of treatment. In seven studies [26, 30–32, 34–36], various adverse events were reported for 49 patients in the control group and for 114 patients in the trial group. All the adverse reactions were mild and did not affect results estimation (Figure 5).

4. Discussion

Broadly speaking, findings of this current review suggested that CHM may have potential positive clinical effect in the treatment of PIC, and the outcome evidence was relatively optimistic for us to make further research to draw a confirmative conclusion.

Three included studies [32, 33, 35] were well-designed, leading to favorable methodological quality and robustness of results. Besides, reporting form and content of these three articles were comprehensive and they basically met the international criteria of CONSORT statement [39]. In other studies, limitations commonly concerned the issue of allocation concealment and blinding. Just like most of the TCM clinical trials, allocation concealment was not reported or not appropriately put into effect in most studies in this review. Only two studies [33, 35] were double-blind and placebo-controlled. Both of them explicitly claimed that outcome assessors and data analyzers were definitely unconscious of interventions that patients received. Placebo is considered as a welcome and reasonable control for effective estimation of CHM [40, 41], because CHM is considered to possess a potential psychological positive effect which is similar to placebo. So if intervention other than placebo is applied as control, the placebo-like effect of CHM may bring out false or exaggerated positive results in favor of the trial group.

Imperfections of included studies also lie in the common absence of sample size calculation. Only three studies [32, 33, 35] estimated sample size. Two studies [26, 27] recruited less than 30 cases in each group, so it was not ensured whether they could provide enough power to detect the difference between groups. In addition, a small sample also might cause

| Study       | CHM Mean | CHM SD | CHM Total | Control Mean | Control SD | Control Total | Mean difference | Mean difference |
|-------------|----------|--------|-----------|--------------|------------|---------------|----------------|----------------|
| An, 2002    | 3.07     | 1.39   | 30        | 4.77         | 0.97       | 30            | 15.6%          | −1.7 [−2.31,−1.09] |
| Huang, 2009 | 2.5      | 0.63   | 30        | 3            | 0.91       | 30            | 36.6%          | −0.5 [−0.9,−0.1]  |
| Song, 2012  | 3.28     | 1.174  | 30        | 4.21         | 1.571      | 30            | 11.7%          | −0.93 [−1.63,−0.23] |
| Wang, 2011  | 3.27     | 1.172  | 30        | 4.2          | 1.562      | 30            | 11.8%          | −0.93 [−1.63,−0.23] |
| Zhang et al., 2008 | 2.84     | 1.47   | 188       | 2.96         | 1.67       | 56            | 24.4%          | −0.12 [−0.61,−0.37] |

Figure 3: Cough relief time analysis.

| Study       | CHM Events | CHM Total | CHM Weight | Control Events | Control Total | Control Weight | Risk ratio M-H, fixed, 95% CI |
|-------------|------------|-----------|------------|----------------|---------------|----------------|----------------------------|
| An, 2012    | 25         | 30        | 12         | 30             | 4.2%          | 2.08 [1.31, 3.32] |
| Huang, 2009 | 19         | 30        | 10         | 30             | 3.5%          | 1.9 [1.07, 3.38] |
| Jiang, in press | 47     | 57        | 16         | 59             | 5.5%          | 3.04 [1.97, 4.7] |
| Jiang, in press | 34     | 57        | 16         | 59             | 5.5%          | 2.2 [1.38, 3.52] |
| Min, 2011   | 62         | 75        | 34         | 73             | 11.9%         | 1.77 [1.36, 2.32] |
| Min, 2011   | 62         | 74        | 34         | 73             | 11.9%         | 1.8 [1.38, 2.35] |
| Qin, 2011   | 25         | 30        | 13         | 30             | 4.5%          | 1.92 [1.24, 2.98] |
| Song, 2012  | 20         | 30        | 11         | 30             | 3.8%          | 1.82 [1.07, 3.1] |
| Wang, 2011  | 20         | 30        | 12         | 30             | 4.2%          | 1.67 [1, 2.76]  |
| Wu, 2011    | 118        | 128       | 95         | 126            | 33.2%         | 1.22 [1.09, 1.37] |
| Zhang et al., 2008 | 121     | 208       | 23         | 69             | 12%           | 1.75 [1.23, 2.48] |

Figure 4: Obvious effective rate analysis.
Table 3: Risk of bias of included studies.

| Study ID        | Adequate sequence generation | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias |
|-----------------|------------------------------|---------------------------------------------|-----------------------------------------|----------------------------------------------------------|-----------------------------------------------|----------------------------------------|--------------------------------------|------------|
| Fujimori et al., 2001 [26] | NS                           | Unclear risk                                | Unclear risk                            | Unclear risk                                            | Low risk                                      | Low risk                               | Low risk                             | High risk   |
| Irifune et al., 2011 [27]    | NS                           | Unclear risk                                | Unclear risk                            | High risk                                               | Low risk                                      | Low risk                               | Unclear risk                         | Unclear risk |
| Qin, 2011 [28]               | NS                           | Unclear risk                                | Unclear risk                            | Unclear risk                                            | Low risk                                      | Low risk                               | Low risk                             | Unclear risk |
| Wang, 2011 [29]              | NS                           | Unclear risk                                | Unclear risk                            | High risk                                               | Low risk                                      | Unclear risk                           | Unclear risk                         | Unclear risk |
| Song, 2012 [30]              | Yes                          | Low risk                                    | Unclear risk                            | Unclear risk                                            | Unclear risk                                  | Unclear risk                           | Unclear risk                         | Unclear risk |
| Wu et al., 2011 [31]         | Yes                          | Low risk                                    | Unclear risk                            | Unclear risk                                            | Unclear risk                                  | Low risk                               | Unclear risk                         | Unclear risk |
| Zhang et al., 2008 [32]      | Yes                          | Low risk                                    | Low risk                                | Low risk                                                | Unclear risk                                  | Unclear risk                           | Low risk                             | Low risk     |
| Wu, 2011 [33]                | Yes                          | Low risk                                    | Low risk                                | Low risk                                                | Unclear risk                                  | Low risk                               | Low risk                             | Low risk     |
| An, 2002 [34]                | NS                           | Unclear risk                                | Unclear risk                            | High risk                                               | Unclear risk                                  | Unclear risk                           | Unclear risk                         | Unclear risk |
| Jiang, 2013 [35]             | Yes                          | Low risk                                    | Low risk                                | Low risk                                                | Low risk                                      | Low risk                               | Low risk                             | Low risk     |
| Min, 2011 [36]               | Yes                          | Low risk                                    | Unclear risk                            | Unclear risk                                            | Unclear risk                                  | Unclear risk                           | Unclear risk                         | Unclear risk |
| Huang, 2009 [37]             | No                           | High risk                                   | Unclear risk                            | Unclear risk                                            | Unclear risk                                  | Low risk                               | Unclear risk                         | Unclear risk |
### Table 4: Evidence qualities of included studies.

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | No. of patients | Chinese herbal medicine | No. of patients | Control | Relative (95% CI) | Absolute | Quality | Importance |
|----------------|--------|--------------|---------------|--------------|-------------|---------------------|-----------------|-------------------------|-----------------|---------|---------------------|----------|---------|------------|
| 5              | Randomised trials | Serious\(^\text{1,2}\) | No serious inconsistency | No serious indirectness | No serious imprecision | None | — | Not pooled |
|                |        |              |               |              |             |                     | 216 162        | —                       | —               | Not pooled | Not pooled | Not pooled | Moderate | Critical |

**Quality assessment**: Cough symptom score (better indicated by lower values)

**Quality of life (QoL) score (better indicated by lower values)**

| 7              | Randomised trials | Serious\(^\text{3}\) | No serious inconsistency | No serious indirectness | No serious imprecision | None | — | Not pooled |
|                |        |              |               |              |             |                     | 585 382        | —                       | —               | Not pooled | Not pooled | Not pooled | Moderate | Critical |

**Quality assessment**: Cough relief time (cough relief time) (better indicated by lower values)

**Quality assessment**: Cough disappearance time (better indicated by lower values)

| 2              | Randomised trials | No serious risk of bias | No serious inconsistency | No serious indirectness | No serious imprecision | None | — | Not pooled |
|                |        |              |               |              |             |                     | 322 128        | —                       | —               | Not pooled | Not pooled | Not pooled | High | Critical |

**TCM syndrome clinical effective rate**

| 9              | Randomised trials | Serious\(^\text{3,4}\) | No serious inconsistency | No serious indirectness | No serious imprecision | None | 687/764 (89.9%) | 357/485 (73.6%) | Not pooled | Not pooled | Not pooled | Not pooled | Moderate | Important |
|                |        |              |               |              |             |                     | —                     | —                       | —               | Not pooled | Not pooled | Not pooled | Moderate | Important |

**Quality assessment**: TCM syndrome clinical effective rate

| 2              | Randomised trials | No serious risk of bias | No serious inconsistency | No serious indirectness | No serious imprecision | None | 144 89        | —                       | Not pooled | Not pooled | Not pooled | Not pooled | High | Important |
|                |        |              |               |              |             |                     | —                     | —                       | —               | Not pooled | Not pooled | Not pooled | High | Important |

\(^1\) Fujimori et al. stopped the study when the significant differences between two groups were detected, which may lead to an overestimation of intervention in the trial group.

\(^2\) Fufune et al. conducted an open-label trial, which would introduce an influence on subjective patient-report results.

\(^3\) An MC and Wang YF conducted an open-label study, which would introduce a bias to subjective patient-report results.

\(^4\) Huang MH conducted a quasirandom method, which would introduce selection bias.
exaggerated difference between groups. Therefore, outcomes in this case should be regarded with caution.

Although the formulas used in the trials included in this review were not completely equivalent, nine of them [28–33, 35–37] were prescribed based on the same fundamental TCM therapeutic principle of “dispelling wind and dispersing the lung-Qi.” Ephedra, Platycodon grandiflorus, Folium perilla, Almond, and Schizonepeta tenuifolia were usually used in prescriptions with this function. The corresponding TCM syndrome of patients is “wind evil attacking the lung,” which
is considered as the most common syndrome in patients with PIC. In addition, TCM therapeutic principles such as nourishing the lung-Yin, resolving phlegm, expelling cold, or eliminating heat were also commonly used for PIC.

Most studies implied good safety of CHM. However, some results should be treated with prudence because only three studies [27, 33, 35] judged the definite relevance between adverse events and corresponding interventions. As a significant complementary and alternative therapeutic method, TCM is traditionally regarded as natural with fewer side effects. Thus, some researchers tend to pay less attention to safety of CHM. But since the toxicological risks of CHM have been observed in many researches [42], more emphasis should be placed on this issue.

In this review, only four studies [26, 27, 33, 35] declared ethical approval and only one study [35] completed clinical trial registration on a publicly accessible database before the trial was set about. Hence, compliance with ethical guideline and trial registration should be addressed in further researches to eventually strengthen the effectiveness and value of scientific evidence.

Although most of the studies in this review authoritatively recommended CHM for PIC, it is impossible to conduct a meaningful meta-analysis to prove the conclusion. Clinical investigators have to consider repeating studies with the same CHM for a powerfully statistical proved conclusion. Decoction, as a complex mixture, is usually prepared artificially. Therefore, the processes of decoction manufacturing and decoction administration are unlikely to realize quality-and-quantity control. Accordingly, the consistency of decoction throughout the whole treatment course is suspected. In addition, if decoction is used as intervention in a research, blinding method is difficult to be implemented for it seems impossible to produce a simulation. Thus, prepared drugs formulated as granules, tables, pills, or capsules are in need to reduce bias in TCM clinical trials.

5. Conclusion

Findings suggest that CHM may effectively improve core symptoms of PIC, act better and have earlier antitussive effect, and enhance patients’ quality of life. CHM is relatively safe and well tolerated without serious side effects. The most common syndrome of patients with PIC is “syndrome of wind evil invading the lung”; correspondingly, “dispelling wind and dispersing the lung-Qi” is the commonest TCM therapeutic principle for PIC. Since some of the studies included in this review were well-designed and comprehensively reported, various limitations still existed. Therefore, confirmative conclusions are not allowed. But current evidence is promising for clinical investigators to do further in-depth researches. Larger-scale, multicentre, placebo-controlled studies for diverse populations are definitely welcomed. Action mechanism of CHM in treatment of PIC, which has been poorly known, needs to be researched to prove the effectiveness and safety of CHM in a more convincing and essential manner.

Conflict of Interests

All authors declare that they have no conflict of interests.

Authors’ Contribution

This project was initiated and designed by Bing Mao, who was also responsible for coordinating and supervising this review. Wei Liu and Hong Li Jiang were involved in the performance and development of this review. All authors have read and approved the final paper.

Acknowledgment

The current work was partially supported by the Administrative Bureau of Traditional Chinese Medicine in Sichuan province.

References

[1] S. S. Braman, “Postinfectious cough: ACCP evidence-based clinical practice guidelines,” Chest, vol. 129, no. 1, pp. 1385–1465, 2006.
[2] N.-H. Kwon, M.-J. Oh, T.-H. Min, B.-J. Lee, and D.-C. Choi, “Causes and clinical features of subacute cough,” Chest, vol. 129, no. 5, pp. 1142–1147, 2006.
[3] R. S. Irwin and J. M. Madison, “The diagnosis and treatment of cough,” The New England Journal of Medicine, vol. 343, no. 23, pp. 1715–1721, 2000.
[4] P. W. Robertson, H. Goldberg, and B. H. Jarvie, “Bordetella pertussis infection: a cause of persistent cough in adults,” Medical Journal of Australia, vol. 146, no. 10, pp. 522–525, 1987.
[5] S. F. Davis, R. W. Sutter, P. M. Strebel et al., “Concurrent outbreaks of pertussis and Mycoplasma pneumoniae infection: clinical and epidemiological characteristics of illnesses manifested by cough,” Clinical Infectious Diseases, vol. 20, no. 3, pp. 621–628, 1995.
[6] N. M. Ryan, A. E. Vertigan, J. Ferguson, P. Wark, and P. G. Gibson, “Clinical and physiological features of postinfectious chronic cough associated with H1N1 infection,” Respiratory Medicine, vol. 106, no. 1, pp. 138–144, 2012.
[7] K. Leder, M. I. Sinclair, T. Mitakakis, M. E. Hellard, A. Forbes, and C. K. Fairley, “A community-based study of respiratory episodes in Melbourne, Australia,” Australian and New Zealand Journal of Public Health, vol. 27, no. 4, pp. 399–404, 2003.
[8] T. Ishida, T. Yokoyama, M. Iwasaku et al., “Clinical investigation of postinfectious cough among adult patients with prolonged cough,” Nihon Kokyuki Gakkai Zasshi, vol. 48, no. 3, pp. 179–185, 2010.
[9] B. Zimmerman, F. S. Silverman, S. M. Tarlo, K. R. Chapman, J. M. Kubay, and B. Urch, “Induced sputum: comparison of postinfectious cough with allergic asthma in children,” Journal of Allergy and Clinical Immunology, vol. 105, no. 3, pp. 495–499, 2000.
[10] Y. To, M. Dohi, R. Tanaka, A. Sato, K. Nakagome, and K. Yamamoto, “Early interleukin 4-dependent response can induce airway hyperreactivity before development of airway inflammation in a mouse model of asthma,” Laboratory Investigation, vol. 81, no. 10, pp. 1385–1396, 2001.
[11] R. Betz, M. Kohlhauff, G. Kassner et al., “Increased sputum IL-8 and IL-5 in asymptomatic nonspecific airway hyperresponsiveness,” *Lung*, vol. 179, no. 2, pp. 119–133, 2001.

[12] Y. S. Cho, S. Y. Park, C.-K. Lee et al., “Enhanced cough response to hyperpnea with cold air challenge in chronic cough patients showing increased cough sensitivity to inhaled capsaicin,” *Allergy*, vol. 58, no. 6, pp. 486–491, 2003.

[13] R. H. Poe, R. V. Harder, R. H. Israel, and M. C. Kallay, “Chronic persistent cough. Experience in diagnosis and outcome using an anatomic diagnostic protocol,” *Chest*, vol. 95, no. 4, pp. 723–728, 1989.

[14] L.-P. Boulet, “Future directions in the clinical management of cough: ACCP evidence-based clinical practice guidelines,” *Chest*, vol. 129, no. 1, pp. 287S–292S, 2006.

[15] L.-P. Boulet, “The current state of cough research: the clinician's perspective,” *Lung*, vol. 186, no. 1, pp. S17–S22, 2008.

[16] C. Lefebvre, E. Manheimer, and J. Glanville, “Chapter 6: searching for studies,” in *Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0*, J. P. T. Higgins and S. Green, Eds., Cochrane Collaboration, Oxford, UK, 2011.

[17] Asthma Study Group, Committee of Respiratory Disease, Chinese Medical Association, “Guideline: diagnosis and management of cough (version 2009),” *Chinese Journal of Tuberculosis and Respiratory Diseases*, vol. 32, no. 6, pp. 407–413, 2009.

[18] X. Y. Zheng, *Guiding Principle of Clinical Research on New Drugs of Traditional Chinese Medicine* (Trial Implementation), Chinese Medical Science and Technology Press, Beijing, China, 2002.

[19] Z.-X. Bian, D. Moher, Y.-P. Li et al., “ Appropriately selecting and concisely reporting the outcome measures of randomized controlled trials of traditional Chinese medicine,” *Journal of Chinese Integrative Medicine*, vol. 6, no. 8, pp. 771–775, 2008.

[20] C. T. French, R. S. Irwin, K. E. Fletcher, and T. M. Adams, “Evaluation of a cough-specific quality-of-life questionnaire,” *Chest*, vol. 121, no. 4, pp. 1123–1131, 2002.

[21] S. S. Birring, B. Prudon, A. J. Carr, S. J. Singh, L. Morgan, and I. D. Pavord, “Development of a symptom specific health status measure for patients with chronic cough: Leicester cough questionnaire (LCQ),” *Thorax*, vol. 58, no. 4, pp. 339–343, 2003.

[22] J. P. T. Higgins and S. Green, *Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0*, The Cochrane Collaboration, 2011, http://handbook.cochrane.org/.

[23] A. D. Oxman, “ Grading quality of evidence and strength of recommendations,” *British Medical Journal*, vol. 328, no. 7454, pp. 1490–1494, 2004.

[24] H. Schunemann, J. Brozek, and A. Oxman, Eds., GRADE Handbook for Grading Quality of Evidence and Strength of Recommendation. Version 3.2, The GRADE Working Group, 2009, http://www.gcd-ims.org/gradepro.

[25] J. P. Higgins and S. Green, Eds., *Cochrane Handbook for Systematic Reviews of Interventions*, The Cochrane Collaboration, 5.1.0 edition, 2011.

[26] K. Fujimori, E. Suzuki, and F. Gejyo, “ Comparison between Bakumondo-tó(Mai men dong tang) and Detromethorphan Hydrobromide in terms of effect on postinfectious cough: a pilot study,” *Japanese Journal of Oriental Medicine*, vol. 51, no. 4, pp. 725–732, 2001.

[27] K. Irifune, H. Hamada, R. Ito et al., “ Antitussive effect of bakumondo a fixed kampo medicine (six herbal components) for treatment of post-infectious prolonged cough: controlled clinical pilot study with 19 patients,” *Phytotherapy*, vol. 18, no. 8-9, pp. 630–633, 2011.

[28] T. Qin, *Clinical Observation Treatment for Wind and Sputum Evil Invading Lung-Postinfectious Cough by E Li Soup*, Guangzhou University of Chinese Medicine, 2011.

[29] Y. F. Wang, *The Clinical Research of Treatment of Shufeng Xuanfei Decoction in Post-Infectious Cough*, Nanjing University of Chinese Medicine, 2011.

[30] R. P. Song, *The Clinical Research of Qingfei Zhike Decoction for Treatment of Post-Infectious Cough (Syndrome of Wing-Heat Attacking Lung)*, Beijing University of Chinese Medicine, 2012.

[31] W. Wu, B. Wang, W. Wang, and F. Gao, “ The clinical research for treatment of post-infectious cough with Shufeng Xuanfei method,” *Modern Journal of Integrated Traditional Chinese and Western Medicine*, vol. 20, no. 24, pp. 3051–3052, 2011.

[32] Y.-P. Zhang, Y. Chao, and Q. Miao, “ Randomized controlled study on suhuang zhike capsule for treatment of post-cold cough,” *Chinese Journal of Integrated Traditional and Western Medicine*, vol. 28, no. 8, pp. 698–701, 2008.

[33] L. Wu, *Clinical Research on TCM Syndrome Differentiation Treatment of Post Infectious Cough*, Guangzhou University of Chinese Medicine, 2011.

[34] M. C. An, *The Clinical Observation on Postinfectious Cough of Wind-Evil Invading Lung Treatment with Zhikegubiao Method*, Shandong University of Chinese Medicine, 2002.

[35] H. L. Jiang, “ The clinical observation of effectiveness and safety of QingfengGanke Granules for treatment of postinfectious cough(syndrome of wind-evil attacking the lung) a phase randomized, double-blind, dose parallel-controlled, multicenter trial,” In press.

[36] C. Y. Min, “ Effect of ButuXuanf ei formula for 75 cases of cough induced by common cold,” *Journal of Traditional Chinese Medicine*, vol. 52, no. 7, pp. 572–574, 2011.

[37] M. H. Huang, *The Clinical Observation to Treat Cough after Influenza of Wind Evil Encroach Lung-Hyperactivity Injuries Body-Fluitype with Ke Ping Tang Recipe*, Fujian College of Chinese Medicine, 2009.

[38] State Chinese Medicine Administration Bureau (SATCM), *Disease Diagnosis Standard of TCM Curative Effect*, Nanjing University Press, Nanjing, China, 1994.

[39] K. F. Schulz, D. G. Altman, and D. Moher, “ CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials,” *BMC Medicine*, vol. 8, article 18, 2010.

[40] J.-J. Fu, G. Wang, and B. Mao, “ The assessment of scientificality and ethics of placebo-controlled trials in traditional Chinese medicine,” *Chinese Journal of Evidence-Based Medicine*, vol. 8, no. 9, pp. 781–785, 2008.

[41] Y. Q. Zhong, J. J. Fu, X. M. Liu et al., “ The reporting quality, scientific rigor, and ethics of randomized placebo-controlled trials of traditional Chinese medicine compound formulations and the differences between Chinese and non-Chinese trials,” *Current Therapeutic Research*, vol. 71, no. 1, pp. 30–49, 2010.

[42] D. Shaw, “Toxicological risks of Chinese herbs,” *Planta Medica*, vol. 76, no. 17, pp. 2012–2018, 2010.